toripalimab,nivolumab,tegafur,oxaliplatin,oteracil,gimeracil,capecitabine
nordic group,bms,coherus,otsuka,ono pharma,junshi biosciences
['nivo', 'toripalimab', 'gastric', 'nivolumab', 'attraction-5', 'gi ']
perhaps tumor presence is important for efficacy of periopative io resectable gastric/gej cancer? adjuvant nivolumab (attraction-5) negative for rfs but peri-operative toripalimab positive with higher tumor regression scores. #asco23 #uppergi 
GI Oncologist at @IUCancerCenter. @uw_hemeoncpc and @UChicagomed alum. Tweets are my own.